December 11, 2009 (FinancialWire) — Dendreon Corp. (NASDAQ: DNDN) has hired Hans Bishop as its chief operating officer, effective January 4, 2010. Bishop most recently served as president of the specialty medicine business at Bayer, where he was responsible for a portfolio of oncology, hematology, and neurology products.

Bishop also served as an executive vice president of Bayer HealthCare.

Seattle-based Dendreon is a biotechnology company engaged in the discovery, development and commercialization of novel therapeutics.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.